Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 11/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAP2 | P11137 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676408 | 0.81 | BRD4 (0.48) | ALDH1A1BRD4SMN1; SMN2 | |
| SCHEMBL676819 | 0.80 | ALDH1A1 (0.49) | ALDH1A1BRD4SMN1; SMN2 | |
| SCHEMBL676158 | 0.79 | ALK (0.50) | ALDH1A1BRD4SMN1; SMN2 | |
| SCHEMBL674903 | 0.76 | ROCK2 (0.50) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL15873503 | 0.75 | CHUK (0.54) | ALDH1A1MAP2CSF1R | |
| SCHEMBL13460985 | 0.75 | JAK2 (0.52) | ALDH1A1MAP2CSF1R | |
| SCHEMBL676235 | 0.75 | JAK2 (0.52) | ALDH1A1MAP2CSF1R | |
| SCHEMBL675881 | 0.74 | ADORA2A (0.45) | ALDH1A1BRD4 | |
| SCHEMBL678785 | 0.74 | DYRK1A (0.44) | MAP2 | |
| SCHEMBL674243 | 0.72 | GABRA1 (0.47) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | ALDH1A1 749/4885BRD4 944/4885SMN1; SMN2 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.